/
AMGN
$386.40+$0.00 (+0.00%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$209.2B
540M shares
52-week range
$269.77 – $398.00
91% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change+$147.85
Amgen Inc
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
www.amgen.com- Employees
- 31,500
- IPO / List date
- Jun 17, 1983
- HQ
- THOUSAND OAKS, CA
Held by traders on TradeandTell
No one on the platform currently holds AMGN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 167,245 | $47.2M |
| Bridgewater Associatesas of 2026-03-31 | 14,774 | $5.2M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 2.57% ($9.94/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-21 | $2.5200 | 2026-09-11 |
| 2026-05-15 | $2.5200 | 2026-06-05 |
| 2026-02-13 | $2.5200 | 2026-03-06 |
| 2025-11-21 | $2.3800 | 2025-12-12 |
| 2025-08-22 | $2.3800 | 2025-09-12 |
| 2025-05-16 | $2.3800 | 2025-06-06 |
| 2025-02-14 | $2.3800 | 2025-03-07 |
| 2024-11-18 | $2.2500 | 2024-12-09 |
| 2024-08-16 | $2.2500 | 2024-09-06 |
| 2024-05-16 | $2.2500 | 2024-06-07 |
Recent trades on TradeandTell
No one on the platform has traded AMGN yet.
